Clinical Trial Update: Pembrolizumab and Olaparib in Cervical Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab with olaparib in cervical cancer has been terminated; results were posted on 2025-04-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Cervical Cancer, Cervical Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-29